2 results match your criteria: "French Clinical Oncopharmacology Group (GPCO)-UNICANCER[Affiliation]"
Reply to: "Is uracil enough for effective pre-emptive DPD testing?".
Clin Chem Lab Med
November 2024
French Clinical Oncopharmacology Group (GPCO)-UNICANCER, Paris, France.
Can we identify patients carrying targeted deleterious variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis.
Clin Chem Lab Med
November 2024
Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France.
Objectives: Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of severe fluoropyrimidine-related toxicities. The best strategy for identifying DPD-deficient patients is still not defined. The EMA recommends targeted genotyping or uracilemia (U) testing.
View Article and Find Full Text PDF